Editor's Corner

Anyone looking for some real insight into the FDA's ongoing effort to rehabilitate its reputation need only look at the two reports below that outline the agency's latest debacles. In one case, regulators following the mandates of an industry-friendly guideline appear poised to approve a powerful antibiotic for veterinarian use that is needed to protect human health. And the agency's effort to track post-marketing drug safety has failed, leaving staffers to rely on an inherently unreliable system. All this from an agency that was intended to make drug safety a top issue. It is difficult to expect too much from any government bureaucracy, but this latest let-down affects the entire drug development industry. If the FDA can't be relied on to track post-marketing safety, then the entire biopharma industry has to continue to suffer from a public backlash against the drug industry that could have a far-reaching impact on pricing and further regulation.

On another note, I want to thank everyone who tuned in for our webinar on economic development last week. We had a great turnout and an interesting discussion on the latest trends. Here's a link to the webinar, in case you missed it. - John Carroll

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.